Company history

Cinclus Pharma AB

Trädgårdsgatan 54

431 35 Mölndal

SWEDEN

info@cincluspharma.com

Kjell Andersson, CEO

+46 733 337 906


Peter Unge, CMO

+46 705 763 780

Copyright © All Rights Reserved

Company history and investors

Cinclus Pharma AB is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Its drug candidate X842 has successfully completed a phase I clinical study.

 

The company was founded in 2014 by Kjell Andersson, Peter Unge, Lennart Hansson, Mikael Dahlström, Urban Paulsson and Marek Poszepczynski.

 

The members of Cinclus Pharma’s management team were key members of the project teams that developed AstraZeneca’s blockbuster drugs Losec and Nexium.


Cinclus is latin for the European dipper.  

Photo: Thomas Lundquist

Background

During 2001-2005 AstraZeneca performed 23 phase I and two phase II clinical studies of its P-CAB drug candidate linaprazan in over 2,500 patients. The studies showed that linaprazan was well tolerated, with a fast onset of action and full effect already at first dose. However, linaprazan was quickly eliminated from the body and the duration of acid blocking was too short. Consequently, AstraZeneca decided to shut down the linaprazan project.

 

One of the founders of Cinclus Pharma, Kjell Andersson, was at that time preclinical project leader at AstraZeneca. Together with his colleague Mikael Dahlström, he acquired the rights to the prodrugs of linaprazan. One such prodrug is X842. The compound provides a longer half-life in the body than linaprazan itself, provides total control of gastric acid production and is tailored for GERD patients with severe esophagitis.

 

Cinclus Pharma has performed its first clinical study of X842 with positive results and is now to launch a comprehensive and de-risked clinical development program to progress its drug candidate towards registration. The successful launch by Takeda of the first P-CAB drug, Takecab, in Japan has further proven the high unmet medical need highlighting the potential for X842.

 

A first licensing agreement is already in place with Jiangsu Sinorda Biomedicine Ltd, covering China and certain other territories in South East Asia.

Shareholder base

The shareholder base of Cinclus Pharma includes investors like Recipharm Venture Fund AB. Management holds 29% of the ownership.